Skip to main content
. 2021 Dec 1;9(12):1811. doi: 10.3390/biomedicines9121811

Table 4.

Multivariate Cox regression analysis, regarding MM patients overall and progression-free survival.

Covariate HR 1 95% CI 2 p Value 3 BCa 4 Bootstrap 5 95% CI 2 Bootstrap 5 p Value 3
Overall survival (OS) i-tRF-ProTGG status
Positive 1.00
Negative 4.06 1.28–12.82 0.0 17 0.98–46.70 0.011
R-ISS 6 (ordinal) 3.39 1.28–8.96 0.0 14 0.93–38.24 0.024
i-tRF-GluCTC status
Positive 1.00
Negative 5.87 1.75–19.63 0.0 04 1.02–5.58 × 105 0.001
R-ISS 6 (ordinal) 3.98 1.50–10.57 0.006 0.58 –7.39 × 105 0.010
i-tRF-HisGTG status
Positive 1.00
Negative 6.49 1.94–21.74 0.0 02 0.97–7.32 × 105 0.001
R-ISS 6 (ordinal) 3.77 1.44–9.91 0.0 07 0.87–4.42 × 105 0.008
Progression-free survival (PFS) i-tRF-GlyGCC status
Positive 1.00
Negative 3.06 1.33–7.00 0.008 1.12–12.63 0.0 07
ISS 7 (ordinal) 2.22 1.25–3.95 0.0 07 1.20–7.71 0.008
3′-tRF-LeuAAG/TAG status
Positive 1.00
Negative 2.94 1.32–6.55 0.008 1.28–8.76 0.005
ISS 7 (ordinal) 2.16 1.22–3.80 0.008 1.21–6.37 0.008

1 Hazard ratio; 2 Confidence interval; 3 Italics indicate a significant p value; 4 Bias-corrected and accelerated; 5 Based on 1000 bootstrap samples; 6 Revised International Staging System; 7 International Staging System.